BR112012008518A2 - derivado heterocíclico, e, composição farmacêutica - Google Patents

derivado heterocíclico, e, composição farmacêutica

Info

Publication number
BR112012008518A2
BR112012008518A2 BR112012008518A BR112012008518A BR112012008518A2 BR 112012008518 A2 BR112012008518 A2 BR 112012008518A2 BR 112012008518 A BR112012008518 A BR 112012008518A BR 112012008518 A BR112012008518 A BR 112012008518A BR 112012008518 A2 BR112012008518 A2 BR 112012008518A2
Authority
BR
Brazil
Prior art keywords
heterocyclic derivative
pharmaceutical composition
heterocyclic
present
derivative
Prior art date
Application number
BR112012008518A
Other languages
English (en)
Portuguese (pt)
Inventor
Fiona Jeremiah
John Kinnaird Ferguson Maclean
Paul David Ratcliffe
Thomas Rusell Clarkson
Original Assignee
Msd Oss Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Oss Bv filed Critical Msd Oss Bv
Publication of BR112012008518A2 publication Critical patent/BR112012008518A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112012008518A 2009-10-13 2010-10-11 derivado heterocíclico, e, composição farmacêutica BR112012008518A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25110109P 2009-10-13 2009-10-13
EP09172872 2009-10-13
PCT/EP2010/065160 WO2011045258A1 (en) 2009-10-13 2010-10-11 Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor

Publications (1)

Publication Number Publication Date
BR112012008518A2 true BR112012008518A2 (pt) 2016-04-05

Family

ID=42040651

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012008518A BR112012008518A2 (pt) 2009-10-13 2010-10-11 derivado heterocíclico, e, composição farmacêutica

Country Status (12)

Country Link
US (1) US8841289B2 (cg-RX-API-DMAC10.html)
EP (1) EP2488520B1 (cg-RX-API-DMAC10.html)
JP (1) JP2013507417A (cg-RX-API-DMAC10.html)
KR (1) KR20120100913A (cg-RX-API-DMAC10.html)
CN (1) CN102666540A (cg-RX-API-DMAC10.html)
AU (1) AU2010305825A1 (cg-RX-API-DMAC10.html)
BR (1) BR112012008518A2 (cg-RX-API-DMAC10.html)
CA (1) CA2776835A1 (cg-RX-API-DMAC10.html)
IN (1) IN2012DN02968A (cg-RX-API-DMAC10.html)
MX (1) MX2012004289A (cg-RX-API-DMAC10.html)
RU (1) RU2012119488A (cg-RX-API-DMAC10.html)
WO (1) WO2011045258A1 (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014001265A2 (pt) 2011-07-29 2017-02-21 Taisho Pharmaceutical Co Ltd composto de amidina ou seu sal
RU2696572C2 (ru) 2012-03-07 2019-08-05 Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение
CA2874193A1 (en) * 2012-05-22 2013-11-28 Vladimir BAJIC Combination comprising parthenolide for use in the treatment of alzheimer's disease and other neurodegenerative disorders
CA2922469A1 (en) 2013-09-11 2015-03-19 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
WO2016034703A1 (en) 2014-09-05 2016-03-10 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
CA2971413A1 (en) 2014-12-16 2016-06-23 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
EP3253765A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
EP3253738A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
HK1248221A1 (zh) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 异噻唑啉酮类，吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂
CN106146410B (zh) * 2015-04-03 2018-10-12 中南大学 6-氨基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
CN106279211B (zh) 2015-06-03 2020-09-15 北京大学 一种噻唑并嘧啶酮化合物及其制备方法和应用
CN107847494A (zh) 2015-06-10 2018-03-27 阿考温特科学股份有限公司 作为α7‑烟碱乙酰胆碱受体激动剂的氨基苯并异噁唑化合物
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
ES2821010T3 (es) * 2015-12-09 2021-04-23 Cadent Therapeutics Inc Moduladores heteroaromáticos del receptor NMDA y usos de los mismos
WO2017100599A1 (en) 2015-12-09 2017-06-15 Luc Therapeutics Thienopyrimidinone nmda receptor modulators and uses thereof
AU2017382339B2 (en) 2016-12-22 2024-02-15 Novartis Ag NMDA receptor modulators and uses thereof
WO2020004594A1 (ja) * 2018-06-27 2020-01-02 株式会社リボルナバイオサイエンス 脊髄性筋萎縮症の予防または治療剤
HU231414B1 (hu) * 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
CA3102326A1 (en) 2018-07-26 2020-01-30 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4
PT3830092T (pt) 2018-08-03 2023-07-25 Novartis Ag Moduladores do recetor nmda heteroaromáticos e suas utilizações
WO2021198191A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
EP4126847A1 (en) 2020-03-30 2023-02-08 ENYO Pharma Quinazolinone derivatives and uses thereof for treating a cancer
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
CN112898290B (zh) * 2021-01-29 2022-08-05 中南大学 异噁唑甲酰胺基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
EP4584258A1 (en) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
TW202539670A (zh) * 2024-02-23 2025-10-16 大陸商海思科醫藥集團股份有限公司 Braf抑制劑的製備方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
CA2444598A1 (en) * 2001-04-20 2003-10-31 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of gsk-3
EP1472248A1 (en) 2002-01-17 2004-11-03 Eli Lilly And Company Modulators of acetylcholine receptors
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
TW200536830A (en) * 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
PT1910333E (pt) * 2005-07-26 2013-08-01 Sanofi Sa Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase
NZ575426A (en) 2006-09-11 2010-09-30 Organon Nv Quinazolinone and isoquinolinone acetamide derivatives useful for the treatment of disorders which are influenced by modulation of the activity of the hpa axis
ATE502027T1 (de) * 2006-12-27 2011-04-15 Sanofi Aventis Substituierte isochinoline und ihre verwendung als rho-kinase-inhibitoren
JP2010229035A (ja) * 2007-08-01 2010-10-14 Taisho Pharmaceutical Co Ltd ピリドピリミジン−４−オン誘導体
CA2705752A1 (en) * 2007-11-14 2009-05-22 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use
EP2249455A1 (en) 2008-02-29 2010-11-10 Techno Core International Co., Ltd. Charging device and quality judging device of pack cell

Also Published As

Publication number Publication date
RU2012119488A (ru) 2013-11-20
JP2013507417A (ja) 2013-03-04
CA2776835A1 (en) 2011-04-21
IN2012DN02968A (cg-RX-API-DMAC10.html) 2015-07-31
KR20120100913A (ko) 2012-09-12
CN102666540A (zh) 2012-09-12
US8841289B2 (en) 2014-09-23
AU2010305825A1 (en) 2012-04-19
MX2012004289A (es) 2012-06-12
US20120208796A1 (en) 2012-08-16
WO2011045258A1 (en) 2011-04-21
EP2488520A1 (en) 2012-08-22
EP2488520B1 (en) 2015-09-02

Similar Documents

Publication Publication Date Title
IN2012DN02968A (cg-RX-API-DMAC10.html)
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
BRPI0811280B8 (pt) compostos amino-heterocíclicos, composição farmacêutica que os compreende e usos dos referidos compostos
IN2014DN03206A (cg-RX-API-DMAC10.html)
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
BRPI1015568B8 (pt) derivados de imidazolidin-2-ona 1,3-dissubstituídos como inibidores de cyp 17, seus usos, e composição farmacêutica
ECSP099177A (es) Derivados de quinazolinona e isoquinolinona
ATE557015T1 (de) 3,4-diarylpyrazole als proteinkinaseinhibitoren
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
MX2011012337A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades.
BR112012012529A2 (pt) composto indol e seu uso farmacêutico
BRPI1011657A2 (pt) derivados aminopropiônicos substituídos como inibidores de neprilisina
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
CL2012000708A1 (es) Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades.
MX367131B (es) Sales de xantilio 3,6-disustituidas.
MX2011009847A (es) Agentes antihelminticos y su uso.
BR112012006387A2 (pt) aminas de triazol fundidas como moduladores de p2x7
BR112012003464B8 (pt) compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica
MX2009013501A (es) Compuestos piperidinicos y sus usos.
BRPI0511874A (pt) derivados da pirrolopiridina
UY29301A1 (es) Derivados amida
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]